User Base and Market Position - As of June 30, 2023, MedSci Healthcare Holdings Limited has approximately 3.0 million registered physician users on its platform, with an average of about 2.8 million monthly active users[6]. - The platform has a high proportion of senior physician users, with 72% of registered physicians holding the title of Associate Chief Physician or above, according to the National Health Commission of China[6]. - The company served 180 pharmaceutical enterprises with its precision omnichannel marketing and RWS services, covering 336 pharmaceutical-related products[103]. - The doctor platform business continues to show stable growth, providing comprehensive support for medical professionals[104]. - The company plans to strengthen its leading position in the doctor platform through internal innovation and external acquisitions in the second half of 2023[108]. - The company aims to create specialized platforms for different medical fields to enhance user experience and value[107]. Financial Performance - Total revenue for the period reached RMB 151,400,000, with contributions from physician platform solutions (RMB 43,876,000), precision omnichannel marketing solutions (RMB 85,523,000), and real-world research solutions (RMB 22,001,000)[44]. - The company’s financial position shows a significant recovery with total comprehensive income of RMB 54,456 thousand for the period[34]. - The company’s revenue increased by approximately 11.9% from RMB 135.3 million in the six months ended June 30, 2022, to RMB 151.4 million in the same period of 2023[127]. - Gross profit for the six months ended June 30, 2023, was approximately RMB 88.3 million, an increase of about 8.2% compared to RMB 81.6 million for the same period in 2022[127]. - The net profit for the six months ended June 30, 2023, was approximately RMB 11.9 million, a significant recovery from a net loss of approximately RMB 107.2 million in the same period of 2022[127]. - The adjusted net profit for the six months ended June 30, 2023, was approximately RMB 12.2 million, an increase of about 15.5% compared to RMB 10.6 million for the same period in 2022[127]. Assets and Liabilities - As of June 30, 2023, the company reported a net asset value of RMB 1,129,082 thousand, compared to a net liability of RMB (142,264) thousand as of December 31, 2022[32]. - The total non-current liabilities decreased to RMB 2,345 thousand from RMB 724,975 thousand, primarily due to the absence of convertible redeemable preferred shares[32]. - The total assets as of June 30, 2023, were reported at RMB 29,786,000, compared to RMB 37,720,000 as of December 31, 2022[65]. - The company had no bank borrowings or interest-bearing debts, with lease liabilities totaling approximately RMB 7.6 million[148]. - The company had no significant capital commitments as of June 30, 2023[170]. - The company has no significant contingent liabilities as of June 30, 2023[191]. Shareholder and Equity Information - Major shareholders include Microhealth Limited with a 29.30% stake and Dtx Health Limited with a 23.32% stake as of June 30, 2023[24]. - The company’s equity attributable to owners increased significantly, with reserves rising to RMB 1,128,692 thousand from RMB (195,686) thousand[32]. - The total issued share capital as of June 30, 2023, was RMB 420 thousand, reflecting an increase from previous periods[34]. - The company has implemented an employee equity incentive plan, with economic benefits capped at 20% of the relevant shares awarded annually[21]. - The new equity incentive plan ("New Plan") was effective from April 20, 2022, replacing the previous 2021 plan, with Meiyue Limited and Meilong Limited holding 41,848,900 shares and 24,216,550 shares respectively as of April 27, 2023[73]. Research and Development - Research and development expenses for the period included direct employee costs and recurring costs, reflecting the group's commitment to innovation[48]. - Research and development expenses increased by approximately 83.8% from RMB 10.4 million for the six months ended June 30, 2022, to RMB 19.1 million in the same period of 2023, due to a large-scale R&D project initiated in mid-2022[119]. - The company plans to launch its proprietary AI program, MSchat, in the second half of 2023, following internal testing in the first half of 2023[125]. Compliance and Governance - The board confirmed compliance with all applicable corporate governance code provisions since the listing date until June 30, 2023[195]. - The company has no plans to purchase, sell, or redeem any of its listed securities from the listing date until June 30, 2023[197]. - The board can amend, suspend, or terminate the equity incentive plan as per the plan rules[187]. Taxation and Financial Reporting - The effective tax rate for the group’s subsidiaries in mainland China is set at 25%, except for Shanghai Meis Medical, which benefits from a reduced rate of 15% due to its "High-tech Enterprise" status[49]. - The income tax expense increased from approximately RMB -0.2 million for the six months ended June 30, 2022, to approximately RMB 1.0 million for the same period in 2023, mainly due to a decrease in listing-related expenses[161]. - The group implemented the revised International Financial Reporting Standards (IFRS) 17 and IFRS 9 starting January 1, 2023, with no impact on the interim condensed consolidated financial information[40].

Financial Performance - Total revenue for the six months ended June 30, 2023, was approximately RMB 151.4 million, an increase of 11.9% from RMB 135.3 million for the same period in 2022[7]. - Gross profit for the same period was approximately RMB 88.3 million, up 8.2% from RMB 81.6 million in 2022, with a gross margin of 58.3%[15]. - Net profit for the six months ended June 30, 2023, was approximately RMB 11.9 million, a significant recovery from a net loss of RMB 107.2 million in the prior year[15]. - Adjusted net profit for the same period was approximately RMB 12.2 million, representing a 15.5% increase from RMB 10.6 million in 2022[15]. - The net profit margin for the six months ended June 30, 2023, was approximately 7.9%, a recovery from a margin of -79.2% in the previous year[15]. - The company reported a profit before tax of RMB 12,888 thousand for the six months ended June 30, 2023, compared to a loss of RMB 107,445 thousand in the prior year[46]. - The company reported a profit of RMB 11,920,000 for the six months ended June 30, 2023, compared to a loss of RMB 107,198,000 for the same period in 2022[160]. - Adjusted net profit for the same period was RMB 12,213,000, an increase from RMB 10,575,000 year-over-year[160]. User Engagement - The platform had approximately 3.0 million registered physician users as of June 30, 2023, with an average of 2.8 million monthly active users[10]. - The number of active users on the platform reached 180 pharmaceutical companies, utilizing services for 336 related products in the first half of 2023[39]. Business Strategy and Development - The company is set to launch its proprietary AI program, "MeiSi XiaoZhi," in the second half of 2023, following internal testing in the first half[14]. - The company aims to strengthen its leading position in the physician platform market in China through various strategies in the second half of 2023[16]. - The company is actively exploring new business directions through a dual-track strategy of internal development and external acquisitions, aiming to find a second growth curve[19]. - The company aims to enhance the user experience by creating specialized platforms for different medical fields, further refining the platform's value[44]. - The company plans to develop targeted marketing products for innovative medical devices and centralized procurement products in the second half of 2023[42]. Financial Stability - The company reported a significant increase in cash and bank balances, reaching RMB 760,149 thousand, up from RMB 599,266 thousand as of December 31, 2022[26]. - The total equity amounted to RMB 1,129,082 thousand, compared to a deficit of RMB 142,264 thousand in the previous year[27]. - The company’s non-current liabilities decreased to RMB 2,345 thousand from RMB 720,907 thousand, indicating improved financial stability[53]. - The company had no bank borrowings or other interest-bearing debts as of June 30, 2023, resulting in a debt-to-equity ratio of zero[165]. Research and Development - Research and development expenses increased significantly to RMB 19,144 thousand, up from RMB 10,414 thousand, indicating a focus on innovation and product development[46]. - The company’s R&D expenses increased by approximately 83.8% to RMB 19.1 million for the six months ended June 30, 2023, compared to RMB 10.4 million for the same period in 2022, due to several large R&D projects initiated in mid-2022[106]. Taxation and Dividends - The tax rate for Shanghai Meis Medical Technology Co., Ltd. is 15% for the six months ended June 30, 2023, due to its qualification as a "High-tech Enterprise"[68]. - The group incurred a total tax expense of RMB 968 thousand for the six months ended June 30, 2023, compared to a tax credit of RMB 247 thousand for the same period in 2022[93]. - The group has not declared or paid any dividends for the six months ended June 30, 2023, consistent with the previous year[94]. - The group’s tax liabilities are based on the taxable profits generated in the jurisdictions where its subsidiaries operate, with no income tax payable in the Cayman Islands and British Virgin Islands[92]. Revenue Breakdown - Revenue from precision omnichannel marketing solutions rose by approximately 11.9% from RMB 76.4 million to RMB 85.5 million, attributed to expanded customer coverage in response to market conditions and national policy changes[126]. - Revenue from physician platform solutions increased by approximately 18.6% from RMB 37.0 million to RMB 43.9 million, supported by the launch of new products in May 2022 and improved stability of business personnel[127]. - Revenue from RWS solutions increased by approximately 0.6% to RMB 22.0 million for the six months ended June 30, 2023, compared to RMB 21.9 million for the same period in 2022[177].